Faculty of Medical Sciences > Centre for Advanced Research (CFAR) > Research & Publication
Ongoing Research
The Centre for Advanced Research (CFAR) is a premier research centre in frontier areas of modern
biomedical sciences. The objectives of the CFAR are to conduct high quality basic research and training in frontier areas of modern biomedical
sciences, and promote centralized state/national facilities for new and modern techniques in the inter-disciplinary areas of biomedical sciences.
The main research interests of Prof. Shailendra Saxena’s research group is to understand the molecular
mechanisms of host-defense during emerging and reemerging diseases and to develop new predictive, preventive and therapeutic strategies (J. Med Virol,
2022a,b,c; ACS Pharmacol. Transl. Sci. 2021; ACS Chem. Neurosci. 2020; Future Microbiol. 2019; Travel Med Infect Dis. 2019, 2021; J Drug Target. 2017)
for them via various stem cell and cell culture technologies. Prof. Saxena’s research work has been published in various high-impact factor journals
(Science, PNAS, Nature Medicine) with a high number of citations. His group through advanced molecular cell biology techniques has been engaged in
development of various disease models to study the pathogenesis, screening of drug molecules (J Biomol Struct Dyn. 2022; VirusDisease. Springer Nature. 2020)
and to develop potential therapeutics thereof. His group has been actively involved in the risk assessment of the emerging and reemerging diseases involving
its characterization, disease dynamics and pathogenesis in the acute and chronic phase of the disease, leading to mitigate the burden of the disease
((J. Med Virol, 2022a,b,c). Prof. Saxena’s inter- and intra-institutional collaborative researches help clinicians/researchers to investigate clinical/medical
problems amicably. With the immune system appearing increasingly complex (Front. Immunol. 2022) as therapeutic interventions are developed, methods to
identify and track the activity of immune cell types are crucial to determining the effectiveness of new treatments involving novel therapeutics. Dr
Saxena’s group is involved in imaging flow cytometery, which combines the speed and statistical power of flow cytometry, with the visual advantages of
brightfield, darkfield and fluorescent microscopy and stands to revolutionize the ability of researchers and clinicians to monitor immune responses to
therapies in a precise manner not afforded to them by conventional flow cytometry.
Dr. Ashutosh Shrivastava’s research is focused molecular profiling of cancers based on genomics,
transcriptomics, proteomics and metabolomics and therapeutic targets for anticancer drug development. Additionally, Dr. Shrivastava will soon
commence molecular and metabolism-based markers for diagnostics of cancer and inborn errors of metabolism.
Dr. Satyendra Kumar Singh’s research is focused on the adult stem cells, found among all the differentiated
cells in the tissue or organ. These cells can renew itself and can differentiate to yield some or all of the major specialized cell types of the tissue.
Dr. Singh`s aim is to study the role of different transcription factors in self renewal and differentiation of different adult stem cells. His laboratory
is interested in the isolation and characterization of Mesenchymal Stem cells (MSCs) from different mouse and human tissues. We are optimizing conditions
to maintain MSCs stemness in vitro. Undifferentiated MSCs expansion in vitro is very important for proper clinical use. I amusing animal model to study
osteoporosis and application of osteogenic primed MSCs to increase the BMD in osteoporotic patients.Adult Hematopoietic Stem cells (HSCs) and progenitor
cells (HSPCs) are responsible for maintaining the production of blood cells over the life of the animal through a tightly regulated process of proliferation,
self-renewal and differentiation. HSPC have been purified to homogeneity, and their ancestral relationships including specific cell fates and lineage
potential has been established. HSPC development is regulated, in part, by extracellular signals produced by specialized cells in the microenvironment,
which then bind to cell surface receptors present on HSPC to activate intracellular signaling pathways. These interactions promote specific gene expression
programs that regulate survival, growth and differentiation. Transcription factors are required for the survival (Gata-2, Pu.1), proliferation
(c-myb, c-myc, Bmi-1) and differentiation (Pu.1, Ikaros, C/EBP, Gata-1) of HSPC. In addition, transcription factors are frequently mutated or
deregulated in HSPC, and contribute to the initiation and progression of hematopoietic malignancies. Our lab studies are focused on defining the function
of specific transcription factors in normal and leukemic HSPC development, and how these transcription factors activate and repress genes and gene
programs/networks to regulate HSC self-renewal and cell fate and differentiation. We are studying the roles of Cancer Stem Cell (CSCs) in tumor initiation,
progression and metastasis with a emphasis on the cellular and molecular regulators that impact their phenotypical changes and activities in the different
stages of cancer development. We define the cross-talks between CSCs with the tumor microenvironment that support their intrinsic properties including
survival, stemness, quiescence and their cellular and molecular changes in response tovarious therapeutic regimens. Characterization of CSCs using CD24,
CD44, CD90, CD133, CD147, CD166, and CD326 and their hierarchy of development in tumor microenvironment under various stages of disease progression using
various in vitro and in vivo experiments.
Dr Nitu Nigam’s research focus is to identify and characterize the molecular players in chromosomal
aberrations pathways. For this she conducts the genetic screening of affected families in population and utilize cellular /animal models for testing and
validating the hypothesis. Discovery of critical player in genetic disorders (broken, missing, rearranged, or extra chromosomes can diagnose disease and
define treatment options) like thalassemia, Down Syndrome, Williams Syndrome, Philadelphia syndrome, Congenital Birth Defects, Cleft palate, Cleft Lips,
Leukemia’s (ALL, AML, CLL, CML), RSA, Infertility and thalassemia etc undoubtedly the first step towards developing effective therapeutics. With better
understanding of disease producing genes, genetic testing has become a more common place, and diagnosis is extended from not only post-natal period to
prenatal period but even preconception period.
Dr. Anshupriya’s research focus is Forensic fingerprinting. The Forensic fingerprinting laboratory is the
first forensic DNA laboratory in the medical university of Uttar Pradesh. DNA fingerprinting or DNA profiling is considered the gold standard for forensic
human identification (HID) & being widely employed throughout the world in criminal investigations. Apart from forensic human identification (HID), this
technology is also very accurate, and reliable for medical science to diagnose various genetic disorders.The advanced instruments of the laboratory are
used for day-to-day practical, dissertation, hands-on training, and research work for various courses in the Institute of Forensic Science. The laboratory
is a focal point for research and development training for graduate & post-graduatestudents in the advanced methods and techniques used in forensics DNA
analysis. The objectives of the forensic fingerprinting lab:
To provide R & D services for various agencies including private parties, on the appropriate payment in the areas of DNA fingerprinting
for the disputed paternity/maternity cases as well as the exchange of new-born babies’ identification in the hospitaletc.
To establish the identity of unidentified human remains, and in missing persons’ investigations and create the DNA Databank
To establish DNA diagnostic methods for detecting genetic disorders and to develop probes for such detections
To use the DNA fingerprinting technique for the authentication of animal cell lines
To assist police personnel, forensic scientists, lawyers, and the judiciary in understanding the evidential value of DNA profile analysis and related techniques in crime investigation and family matters
To provide an active training and Ph.D. program related to newer DNA fingerprinting techniques to undergraduate & postgraduate students
To establish translational & collaborative research in the areas of DNA fingerprinting to solve the regional, national or international problems
Recent Publications in Indexed Peer Reviewed Journals
1. Saxena SK*, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, Abdel-Moneim AS. Transmission dynamics and mutational prevalence of the novel severe acute respiratory syndrome coronavirus-2 Omicron Variant of Concern. J Med Virol. 2022; 94(5): 2160-2166. doi: 10.1002/jmv.27611. PMID: 35050521.
2. Saxena SK*, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, Abdel-Moneim AS. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022; 94(4): 1738-1744. doi: 10.1002/jmv.27524. PMID: 34905235.
3. Saxena SK*, Ansari S, Maurya VK, Kumar S, Jain A, Paweska JT, Tripathi AK, Abdel-Moneim AS. Re-emerging human monkeypox: A major public-health debacle. J Med Virol. 2022. doi: 10.1002/jmv.27902. Epub ahead of print. PMID: 35652133.
4. Maurya VK, Kumar S, Bhatt MLB, Saxena SK*. Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection. J Biomol Struct Dyn. 2022; 40(4): 1719-1735. doi: 10.1080/07391102.2020.1832577. Epub 2020 Oct 19. PMID: 33073699.
5. Kumar S, Saxena SK*, Maurya VK, Tripathi AK. Progress and challenges toward generation and maintenance of long-lived memory T lymphocyte responses during COVID-19. Front. Immunol. 2022; 12: 804808. doi: 10.3389/fimmu.2021.804808. PMID: 35250966.
6. Singh SP, Sethi R, Saxena SK, Gupta A. Role of metabolomics in identifying cardiac hypertrophy: an overview of the past 20 years of development and future perspective. Expert Rev Mol Med. 2021; 23: e8. doi: 10.1017/erm.2021.12. PMID: 34376261.
7. Kumar S, Maurya VK, Chitti SV, Kabir R, Shanker K, Nayak D, Khurana A, Manchanda RK, Gadugu S, Kumar V, Saxena SK*. Wound healing activity of a novel formulation SKRIN via induction of cell cycle progression and inhibition of PCNA-p21 complex interaction leading to cell survival and proliferation. ACS Pharmacol Transl Sci. 2021; 4(1): 352-364. doi: 10.1021/acsptsci.0c00209. PMID: 33615185
8. Pandey N, Kumar S, Kesar SD, Dandu HR, Ankita, Maurya VK, Kaur A, Saxena SK*. An ophthalmological update for air-travellers during COVID-19. Travel Med Infect Dis. 2021; 39: 101955. doi: 10.1016/j.tmaid.2020.101955. PMID: 33316395.
9. Kar SK, Saxena SK, Kabir R. The relevance of digital mental healthcare during COVID-19: Need for innovations. Nepal J Epidemiol. 2020; 10(4): 928-929. doi: 10.3126/nje.v10i4.32519. PMID: 33495711.
10. Gupta A, Pradhan A, Maurya VK, Kumar S, Theengh A, Puri B, Saxena SK*. Therapeutic approaches for SARS-CoV-2 infection. Methods. 2021; 195: 29-43. doi: 10.1016/j.ymeth.2021.04.026. PMID: 33962011.
11. Kumar S, Saxena SK*. Structural and molecular perspectives of SARS-CoV-2. Methods. 2021; 195: 23-28. doi: 10.1016/j.ymeth.2021.03.007. PMID: 33737214.
26. Saxena SK*, Kumar S., Sharma R., Maurya V.K., Dandu H.R., Bhatt MLB. Zika virus disease in India - Update October 2018. Travel Med Infect Dis. 2019; 27: 121-122. doi: 10.1016/j.tmaid.2018.10.022. PMID: 30399445.
27. Kumar S, Maurya VK, Dandu HR, Bhatt MLB, Saxena SK* Global perspective of novel therapeutic strategies for the management of neuroAIDS. Biomol Concepts. 2018; 9(1): 33-42. doi: 10.1515/bmc-2018-0005. PMID: 29742062.
28. Varghese NM, Senthil V, Saxena SK. Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements. J Drug Target. 2018; 26(3): 195-207. doi: 10.1080/1061186X.2017.1374389. PMID: 28866957.
29. Chitti SV, Prasad AK, Saxena SK*. Emerging Zika virus disease: a public health emergency of global concern. VirusDisease (Springer Nature). 2016; 27(3): 211-214. doi: 10.1007/s13337-016-0317-9. PMID: 28466030.
30. Shyam H., Singh S.K., Kant R., Saxena SK*. Mesenchymal stem cells in regenerative medicine: a new paradigm for degenerative bone diseases. Regenerative Medicine 2017; 12(2): 111-114. doi: 10.2217/rme-2016-0162. PMID: 28244826.
31. Singh N, Verma UP, Chowdhury R, Mishra A, Sahu DK, Shrivastava A, Nandlal and Kant R. (2016) Enumeration and Characterization of Mesenchymal Stem Cells from Age dependent Human Dental Tissue. J Stem Cell Res Ther 6:359.
32. Prasad A*, Kulkarni R*, Shrivastava A, Jiang S, Lawson K, Groopman JE. Methamphetamine functions as a novel CD4 (+) T-cell activator via the sigma-1receptor to enhance HIV-1 infection. Sci Rep. 2019 Jan 30;9(1):958. (*Equal first author).
33. Mishra A, Shrivastava A*, Srivastava A, et al. Prognostic significance of deiodinase enzymes MRNA expression in breast cancer. J. Evid. Based Med. Healthc. 2019; 6(34), 2343-2346.
34. Mishra A, Shrivastava A*. Prognostic Significance of Sodium Iodide Symporter and Deiodinase Enzymes mRNA Expression in Gastric Cancer. Int J Appl Basic Med Res. 2020;10(1):43‐48.
35. Mishra A, Pateriya A, Mishra A, Shrivastava A*. Prognostic significance of autophagy related genes in estrogen receptor positive tamoxifen treated breast cancer. Bioinformation 2020;16(9):710-718 (2020).
36. Singh DK, Panwar S, SaksenaAK, Jaishwal R, Shrivastava A& Kumar R*. (2020). Effect of Turmeric Extract and Fenugreek Seed Extract on Complete Freund’s Adjuvant Induced Arthritis in Rats. International Journal of Health and Clinical Research, 2020;3(9):68-80.
37. Tomar MS, Shrivastava A*. TERT Promotor Mutations Correlate with IDHs, MGMT and EGFR in Glioblastoma Multiforme. Commentary Neurology India. 2020; In press.
38. Nema R, Shrivastava A*, Kumar A*. Prognostic role of lipid phosphate phosphatases in non-smoker, lung adenocarcinoma patients. Comput Biol Med. 2021 Feb; 129:104141.
39. Mohit, Shrivastava A. Chand P. Molecular determinants of obstructive sleep apnea. Sleep Medicine. 2021; 80:105-112
40. Mohit, Shrivastava A, Dutt P, Singh MK, Chand P. COVID-19 exposure and obstructive sleep apnea: A Therapeutic Approach, Sleep Medicine, 2021; (In press)
41. Tandon J, Yadav RK, Tikku AP, Shakya VK, Singh SK. Comparative evaluation of different irrigating and irrigant activation system in removal of gutta-percha/sealer during retreatment: An in vitro Micro-CT study. J Oral Biol Craniofac Res. 2022; 12(4): 444-448. doi: 10.1016/j.jobcr.2022.05.006.
42. Singh A, Kant R, Nandi S, Husain N, Naithani M, Mirza AA, Saluja TS, Srivastava K, Prakash V, Singh SK. Detection of differential expression of miRNAs in computerized tomography-guided lung biopsy. Journal of Cancer Research and Therapeutics. 2022 Jan 1;18(1):231. doi: 10.4103/jcrt.jcrt_749_21
43. Meher RK, Nagireddy PK, Pragyandipta P, Kantevari S, Singh SK, Kumar V, Naik PK. In silico design of novel tubulin binding 9-arylimino derivatives of noscapine, their chemical synthesis and cellular activity as potent anticancer agents against breast cancer. Journal of Biomolecular Structure and Dynamics. 2021 Feb 18:1-2. doi:10.1080/07391102.2021.1889668
44. Bhattacharya A, Champramary S, Tripathi T, Thakur D, Ioshikhes I, Singh SK, Nandi S. Identification of the conserved long non-coding RNAs in myogenesis. BMC genomics. 2021 Dec;22(1):1-9. doi:10.1186/s12864-021-07615-0
45. Tajindra Singh Saluja, Vijay Kumar, Monika Agrawal, Abhilasha Tripathi, Rajesh Kumar Meher, Kamini Srivastava, Anurag Gupta, Anjana Singh, Arun Chaturvedi, Satyendra Kumar Singh. Mitochondrial stress mediated targeting of quiescent cancer stem cells in oral squamous cell carcinoma. Cancer Management and Research, 15 June 2020 Volume 2020:12 Pages 4519—4530 doi: 10.2147/CMAR.S252292
46. Gadomski S, Singh SK, Singh S, Sarkar T, Klarmann KD, Berenschot M, Seaman S, Jakubison B, Gudmundsson KO, Lockett S, Keller JR. Id1 and Id3 maintain steady-state hematopoiesis by promoting sinusoidal endothelial cell survival and regeneration. Cell reports. 2020 Apr 28;31(4):107572.doi: 10.1016/j.celrep.2020.107572
47. Trivedi S, Srivastava K, Gupta A, Saluja TS, Kumar S, Mehrotra D, Singh SK. A quantitative method to determine osteogenic differentiation aptness of scaffold. Journal of Oral Biology and Craniofacial Research. 2020 Apr 1;10(2):158-60. doi: 10.1016/j.jobcr.2020.04.006
48. Singh A, Kant R, Saluja TS, Tripathi T, Srivastava K, Naithani M, Gupta A, Mirza AA, Prakash V, Singh SK. Differential diagnosis of non-small cell lung carcinoma by circulating microRNA. Journal of cancer research and therapeutics. 2020 Jan 1;16(1):127.doi: 10.4103/jcrt.JCRT_872_19
50. Satyendra K. Singh, Singh S, Gadomski S, Sun L, Pfannenstein A, Magidson V, Chen X, Kozlov S, Tessarollo L, Klarmann KD, Keller JR. Id1 ablation protects hematopoietic stem cells from stress-induced exhaustion and aging. Cell Stem Cell. 2018 Aug 2;23(2):252-65. doi.: 10.1016/j.stem.2018.06.001,
51. Gudmundsdottir B, Gudmundsson KO, Klarmann KD, Singh SK, Sun L, Singh S, Du Y, Coppola V, Stockwin L, Nguyen N, Tessarollo L. POGZ is required for silencing mouse embryonic β-like hemoglobin and human fetal hemoglobin expression. Cell reports. 2018 Jun 12;23(11):3236-48. doi: 10.1016/j.celrep.2018.05.043
52. Puverel S, Kiris E, Singh S, Klarmann KD, Coppola V, Keller JR, Tessarollo L. RanBPM (RanBP9) regulates mouse c-Kit receptor level and is essential for normal development of bone marrow progenitor cells. Oncotarget. 2016 Dec 20;7(51):85109. doi: 10.18632/oncotarget.13198
53. Sharma U, Barwal TS, Acharya V, Singh K, Rana MK, Singh SK, Prakash H, Bishayee A, Jain A. Long Non-Coding RNAs as Strategic Molecules to Augment the Radiation Therapy in Esophageal Squamous Cell Carcinoma. International Journal of Molecular Sciences. 2020 Sep 16;21(18):6787.doi.org/10.3390/ijms21186787
54. Hosalkar R, Saluja TS, Swain N, Singh SK. Prognostic evaluation of metastasizing ameloblastoma: A systematic review of reported cases in literature. Journal of Stomatology, Oral and Maxillofacial Surgery. 2021 Apr 1;122(2):192-8.doi : 10.1016/j.jormas.2020.07.001
55. Saluja TS, Iyer J, Singh SK. Leiomyosarcoma: prognostic outline of a rare head and neck malignancy. Oral Oncology. 2019 Aug 1;95:100-5. doi: 10.1016/j.oraloncology.2019.06.010
56. Saluja TS, Ali M, Mishra P, Kumar V, Singh SK. Prognostic value of cancer stem cell markers in potentially malignant disorders of oral mucosa: a meta-analysis. Cancer Epidemiology, Biomarkers & Prevention. 2019 Jan;28(1):144-53.
57. Sinha A, Tripathi S, Nigam N, Kumar M, Singh SN.Profile of neonates born with congenital birth defects in a tertiary care hospital of North India: An observational study.Clinical Epidemiology and Global Health 1490, 2022, 100999.
. Nigam N, Singh PK, Raizada N Singh BP, TripathiS,Agrawal M, Gupta,H, Singh S, Fatima G . Altered pro-inflammatory and anti-inflammatory plasma cytokines levels in children with Down's syndrome: A meta-analysis.J Family Med Prim Care. 2021 Oct; 10(10): 3568–3574.
59. Nigam N, Kushwaha R, Yadav G, Singh PK, Gupta N, Singh B, Agrawal M, Chand P, Saxena SK, Bhatt MLB. A demographic prevalence of β Thalassemia carrier and other hemoglobinopathies in adolescent of Tharu population. J Family Med Prim Care. 2020;9:4305-4310.
60. Nigam N, Singh PK, Agrawal M, Nigam S, Gupta H, Saxena S. MTHFR C677T, Prothrombin G20210A, and Factor V Leiden (G1691A) Polymorphism and Beta-Thalassemia Risk: A Meta-Analysis. Cureus. 2020;12:e10743.
61. Bharti OK, Sood RK, Sharma HR, Kaur H, Minhas V, Chauhan R, Nigam N, Phull A. Mean corpuscular volume/mean corpuscular hemoglobin values are not reliable predictors of the β-thalassemia carrier status among healthy diverse populations of Himachal Pradesh, India. Asian J TransfusSci2020;14:172-8
62. Nigam N, Tripathi S, Agrawal M, Singh PK, Pandey A, Saxena SK. Cytogenetic analysis of down syndrome patients in Eastern Uttar Pradesh. International Journal of Contemporary Medical Research2019;6:J1-J5.
63. Nigam N, Verma N, Agrawal M, Gupta H, Singh PK et al. Correlation of cytogenetic, molecular and clinical findings in thalassemia patients at a tertiary care hospital. J. Evolution Med. Dent. Sci. 2019;8(46):3441-3448
64. Nigam N, Tiwary NK, Agrawal M, Verma SK, Gautam M, Kumar SP, Verma SK, Gupta H. Assessment of knowledge, awareness and attitude regarding fever and mosquito-borne illnesses among secondary and senior secondary school students of rural area of kannauj district in up, north India. J. Evid. Based Med. Healthc. pISSN- 2349-2562, eISSN- 2349-2570/ Vol. 6/Issue 15/April 15, 2019,
65. Gupta H, Nigam N, Kumar S, Kumar A. Keeping it in the family: consanguineous marriage and genetic disorders, from Islamabad to Bradford. BMJ 2019;365 doi: https://doi.org/10.1136/bmj.l1851
66. Fatima G, RazaAM, Hadi N, Nigam N, Mahdi AA. Cadmium in Human Diseases: It’s More than Just a Mere Metal. Indian J ClinBiochem 2019; 34:371–378.
67. Ansari MF, Nigam N, Mishra NK, Singh PK, Kushwaha J, Shyam R, Singh PR, Gupta R. Does clonidine affect the anti-inflammatory response of IL-10 in patients undergoing laparoscopic cholecystectomy? J. Evolution Med. Dent. Sci. 2019;8:3032-3038.
68. Agrawal M, Tiwary NK, Nigam N, Verma SK, Gautam M, Verma DP, Verma SK, Gupta H. Assessment of demographic profile of patients admitted with a diagnosis of alleged self-harm at a teaching hospital in hindiheartland J. Evid. Based Med. Healthc 2019;6 (17):1288-1291.
69. Agrawal M, Nigam N, Goel S, Khan NZ. The role of modified biophysical profile in high risk pregnancies and fetal outcome. International Journal of Biomedical Research 2018; 09(02): 81-85.
70. Gaurav, N Raizada, N. Nigam, D Agarwal, Dr (Brig).T Prabhakar. Inhalational induction with high concentration of sevoflurane in neonates undergoing TEF/EA repair. A comparison of mixture of sevoflurane in 50% N2O/O2 with sevoflurane in 100% o2. International Journal of Contemporary Medical Research 2018;
71. Deo S, Agrawal M, Jaiswar SP, Sankhwar PL, Babu S, Sonalika, Nigam N. Evaluation of etiological factors and management of puberty menorrhagia. International Journal of Biomedical Research 2018;09:112-116.
72. Deo S, Agrawal M, Jaiswar SP, Sankhwar PL, Mahdi AA, Fatnani A, Nigam N. Association of Maternal and cord blood lead level with the feto maternal outcome. International Journal of Scientific Research. 2018;7:58-60.
73. Nigam N, Singh SK, Agrawal M, Pandey A, Verma N, Mohan N, Hussain SR, Singh PK. Cytogenetics: Modern aspects in diagnosis of chromosomal abnormalities in India. International Journal of Scientific Research 2018;7,37-40.
74. Singh S, Raizada N, Nigam N, Elhence A, Gaurav, Prasad SN. Compliance for Transdermal Fentanyl Patch versus Sustained Release Oral Morphine in Cancer Pain. International Journal of Contemporary Medical Research. 2018;5(4):D1-D3.
75. Singh S, Raizada N, Nigam N, Elhence A, Gaurav, Prasad SN. Is Sublingual Buprenorphine ASuccour for Cancer Pain Patient in Centres where Narcotic Licence is Not Permitted. International Journal of Contemporary Medical Research.2018;5:D7-D9.
76. Nigam N, Nigam S, Agarwal M, Singh PK. β-thalassemia: From Clinical Symptoms to the Management, International Journal of Contemporary Medical Research.2017;4:1066-1070.
77. Anjani Kumar, Anshu Priya, Tanzeel Ahmed, Christine Grundström, Neema Negi and Thomas Grundström. Regulation of the DNA repair complex during somatic hyper mutation and class switch recombination. Journal of Immunology; June 15, 200 (12) 4146-41564146-4156;2018 IF-5.43
78. Christine Grundström, Anjani Kumar, Anshu Priya, Neema Negi, Thomas Grundström.ETS1 and PAX5 transcription factors can recruit AID to Igh DNA. Eur Journal of Immunology Oct;48(10) 1687-1697;2018 IF-3.98
79. Priya A, Anjani Kumar, Thomas Grundström et.al., Regulation of diversification and affinity maturation of antibody International Journal of Molecular Medicine2017.IF-3.97
80. Anshu Priya, Kiranjeet Kaur Shalmoli Bhattacharyya, Anuradha Chakraborti, and Sujata Ghosh. Cell cycle arrest and apoptosis induced by enteroaggregative Escherichia coli in cultured human intestinal epithelial cells Journal of Medical Microbiology Mar;66(2) 217-225; 2017 IF-2.53
81. Konar M, Sachin O, Priya Aet al. Identification of key proteins of cultured human intestinal cells involved in interaction with enteroaggregative Escherichia coli.FEMS Immunology Med Microbiology Nov; 66(2)177-90. IF-3.16
(*Corresponding author).